Strong growth and recruitments required more office space

press

Immedica Pharma AB, a pharmaceutical company focused on commercialization of rare and specialty diseases has recently moved its head quarter to the newly established Life City near Torsplan in Stockholm. Immedica is one of several pharmaceutical companies that are located at the new facilities on Solnavägen. According to a report from Stockholms Handelskammare1, the Life […]

Immedica Pharma and Innovative Medicines announces ANMAT (Argentina) and INVIMA (Colombia) filing acceptance of RAVICTI® (glycerol phenylbutyrate), a adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs)

press

Immedica Pharma and Innovative Medicines announces ANMAT (Argentina) and INVIMA (Colombia) filing acceptance of RAVICTI® (glycerol phenylbutyrate), a adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) Immedica Pharma AB, and Innovative Medicines SA, announces two submissions of marketing authorization applications to: The National Agency of Medicines, Food and Medical Technology (ANMAT) […]

Immedica Pharma AB submits Marketing Authorisation Application to the European Medicines Agency seeking approval of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).

press

Stockholm, August 18, 2022 Immedica Pharma AB announced today that the company’s Marketing Authorisation Application for pegzilarginase has been successfully validated by the European Medicines Agency (EMA) for the treatment of patients with Arginase 1 Deficiency (ARG1-D). The application is supported by positive results from the international phase 3 study (CAEB1102-300A, also named PEACE), investigating […]